Novo rises on Wegovy sales leap, but warns of a slowdown
While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating "intensifying competition and continued pricing pressure within diabetes and obesity care" in 2025.
Novo Nordisk A/S expects sales to surge again this year as the Danish drugmaker builds supply for blockbuster diabetes ...
A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans.
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...
Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's ...
They have also become increasingly popular after a number of celebrities began using Ozempic, which is primarily used to treat type 2 diabetes, to lose significant amounts of weight. In the UK, the ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback